Microplastic (MP) contamination in human tissues is an emerging environmental and clinical concern, yet its relevance to organ transplantation remains poorly understood. This study characterized MPs in kidney transplantation-associated donor tissues and examined their relationship with early postoperative blood pressure (BP) in recipients. Tissue samples, including kidney, adrenal gland, renal artery, renal vein, and ureter, were collected from 28 kidney transplant donors. MPs were extracted from each tissue and analyzed using a multimodal strategy: pyrolysis-gas chromatography-mass spectrometry for polymer quantification, laser direct infrared spectroscopy (LD-IR) for particle identification, and scanning electron microscopy (SEM) for morphological assessment. Polyethylene (PE) and polyvinyl chloride (PVC) were consistently the most abundant polymers by mass, with PE concentrations ranging from 25.7 to 98.9 μg/g and PVC from 31.2 to 65.4 μg/g across tissues. LD-IR analysis showed that kidney tissue contained 293 MP particles (6 polymer types), adrenal gland 2017 (9 polymer types), renal artery 881 (8 polymer types), renal vein 1528 (10 polymer types), and ureter 1672 (10 polymer types). MPs measuring 20-100 μm accounted for 47.1-54.9 % of its content across tissues, while 100-500 μm MPs comprised 45.1-52.9 %. Postoperative BP was assessed 15 days post-transplantation. While moderate, tissue-specific correlations between certain MP types and BP were observed (e.g., natural rubber in adrenal glands, polycarbonate in renal arteries, polypropylene in renal veins, and butadiene rubber in ureters), most associations were not statistically significant. Negative values were obtained for linear regression and FDR correction, emphasizing the preliminary nature of the results. This highlights the need for further investigation of the clinical impact of MP.
Background: The ISCHEMIA trial demonstrated no overall prognostic benefit of an initial invasive strategy over optimal medical therapy (OMT) in patients with chronic coronary syndrome (CCS) and moderate-to-severe ischemia. However, managing patients with stable angina and low systolic blood pressure (SBP) remains challenging due to limited tolerance to vasodilatory anti-anginal drugs and the uncertain role of revascularization in improving long-term outcomes for this subgroup. Objectives: This study aimed to estimate the treatment effect of an initial invasive strategy (INV) compared with conservative medical therapy (CON) on long-term clinical outcomes and quality of life in patients with stable angina, particularly those with low baseline systolic blood pressure (≤120 mmHg). Methods: We conducted a post hoc analysis of 3544 patients with stable angina from the ISCHEMIA trial, divided into an initial invasive strategy or a conservative approach. The primary endpoint was a 3-year composite of cardiovascular death, myocardial infarction, hospitalization for unstable angina or heart failure, or resuscitated cardiac arrest. Health-related quality of life was assessed using the Seattle Angina Questionnaire (SAQ). In the subgroup, patients were stratified by baseline SBP, diastolic blood pressure (DBP) and heart rate; the Cox model was adjusted for the covariates. Results: Baseline characteristics were generally comparable between the two groups. Over 3 years of follow-up, no significant difference in primary endpoint events was observed between the INV and CON group in the overall cohort (HR = 0.94, 95%CI 0.77–1.14, p = 0.53), and the INV group had the higher SAQ score. Among patients with low baseline SBP (≤120 mmHg), after adjusting for clinical factors using Cox regression, randomized treatment assignment to the INV approach significantly reduced adverse cardiovascular events compared with conservative therapy (HR = 0.58, 95%CI 0.38 to 0.89). Conclusions: In patients with stable angina, an invasive strategy improved long-term quality of life. Among those with low baseline SBP (≤120 mmHg) and limited tolerance to vasodilatory anti-anginal drugs, invasive management reduced 3-year adverse events, supporting tailored revascularization strategies for these patients; a larger cohort is needed for validation. However, this subgroup-specific causal contrast derives from a post hoc exploratory analysis and should be interpreted cautiously; prospective randomized studies are needed to further validate these findings.